82 FR 35976 - Request for Letters of Interest for NCI-MATCH Laboratories
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health Federal Register Volume 82, Issue 147 (August 2, 2017)
National Institutes of Health
Federal Register Volume 82, Issue 147 (August 2, 2017)
| Page Range | 35976-35978 | |
| FR Document | 2017-16203 |
[Federal Register Volume 82, Number 147 (Wednesday, August 2, 2017)] [Notices] [Pages 35976-35978] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2017-16203] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Request for Letters of Interest for NCI-MATCH Laboratories SUMMARY: The National Cancer Institute (NCI) in collaboration with the NCI Molecular Analysis for Therapy Choice (MATCH) trial leadership (NCT 02465060) invites applications for Clinical Laboratory Improvements Program (CLIA) certified/accredited laboratories that test tumor specimens from patients utilizing Next Generation Sequencing (NGS) assays to participate in the NCI MATCH trial. The NCI MATCH trial has implemented a new process for identifying patients for arms with rare variant eligibility criteria. Laboratories will contact any of the approximately 1100 sites that have activated NCI MATCH if a specimen sent from one of these sites has a rare variant that would potentially make the patient eligible for one of the treatment arms open in this initiative. DATES: LOIs should be submitted to the National Cancer Institute (NCI), National Institutes of Health (NIH) on or before 5:00 p.m. EST on January 31, 2018. ADDRESSES: Submit LOIs by email to NCIMATCHLabApps@nih.gov. 9609 Medical Center Drive, 3 West, Room 526, MSC 9728, Rockville, MD 20892. FOR FURTHER INFORMATION CONTACT: Questions about this request for LOIs should be directed to NCIMATCHLabApps@nih.gov. James V. Tricoli tricolij@mail.nih.gov can also provide further information. SUPPLEMENTARY INFORMATION: NCI-MATCH aims to establish whether patients with tumor mutations, amplifications or translocations in one of the genetic pathways of interest are likely to derive clinical benefit (primary objective: Objective response; secondary objective: Progression-free survival of at least 6 months) if treated with agents targeting that specific pathway in a single-arm design (see current arms below). Patients with histologically documented solid tumors, lymphomas and multiple myeloma whose disease has progressed following at least one line of standard systemic therapy or for whom no standard therapy exists are eligible if they meet the eligibility criteria for the trial. Further information about the NCI-MATCH trial may be found at http://ecog-acrin.org/trials/nci-match-eay131. The selected collaborating laboratories may only act (i.e., refer patients) on any of the rare variant arms for which their assay reports actionable mutations of interest (aMOIs). The assay must also report all exclusionary variants for the arm unless these occur at a frequency of >1% in cancer patients. CLIA accredited/certified laboratories located in the United States may be [[Page 35977]] considered for addition to the laboratory network. Letter of Interest (LOI) and Collaboration Agreement Candidate laboratories should submit a letter of interest to NCIMATCHLabApps@nih.gov stating:Statement of interest in the proposed activity Laboratory name Lead contact name, address, email address, and telephone number CLIA certification number Assay name Brief description of assay [cir] Sensitivity and specificity for SNVs, indels, CNV, fusions [cir] Method of analysis [cir] Platform and variant calling Number of assays per month Number of patients whose assay results would make them potentially eligible for the rare variant arms (below) in the last 6 months Willingness to contact sites regarding results with a rare variant potentially eligible for NCI MATCH Willingness to sign a collaboration agreement with NCI and to share data and publication rights Which arms the laboratory is prepared to address. The arms that are included in the rare variant protocol amendment are: ---------------------------------------------------------------------------------------------------------------- Rare variant candidate MATCH subprotocol (agent) ---------------------------------------------------------------------------------------------------------------- AKT1 mut....................................... EAY131-Y (AZD5363). NF2 loss....................................... EAY131-U (Defactinib). MET amplification.............................. EAY131-C1 (Crizotinib). BRAF V600...................................... EAY131-H (Dabrafenib + Trametinib). SMO/PTCH1...................................... EAY131-T (Vismodegib). BRAF non V600.................................. EAY131-R (Trametinib). EGFR T790M..................................... EAY131-E (AZD9291). ALK translocation.............................. EAY131-F (Crizotinib). cKIT mutation.................................. EAY131-V (Sunitinib). EGFR mutation.................................. EAY131-A (Afatinib). ROS1 translocation............................. EAY131-G (Crizotinib). GNAQ/GNA11..................................... EAY131-S2 (Trametinib). MET exon 14 skipping........................... EAY131-C2 (Crizotinib). NTRK fusions................................... EAY131 Z1E (Loxo101). MTOR mutations................................. EAY131-L (MLN0128). TSC1 or TSC2 mutations......................... EAY131-M (MLN0128). CCND 1,2,3 amplifications...................... EAY131-Z1B (Palbociclib). CDK4 or CDK6 amplification..................... EAY131-Z1C (Palbociclib). DDR2 mutation.................................. EAY131-X (Dasatinib). ---------------------------------------------------------------------------------------------------------------- Following an acceptable eligibility review to the NCI MATCH screening committee, the laboratory would execute a confidentiality agreement with the NCI and will be provided with a detailed list of eligibility and exclusion variants for arms in which the lab has interest. The lab would then be required to submit an application within 3 months for review by the NCI-MATCH steering committee. Candidate laboratories will be required to meet the following general requirements: Testing must be performed in a CLIA-certified or - accredited laboratory located in the United States. Assays must be on tumor tissue only (including lymphoma and myeloma). Assays using circulating nucleic acids will not be accepted at this time. Laboratory NGS panels must be analytically and clinically validated, with performance characteristics as follows: [cir] Specificity at least 99% for single nucleotide variants, indels [cir] Sensitivity at least 95% for single nucleotide variants, indels [cir] Sensitivity of 90% for copy number variants (state fold of copy number variants that can be detected with 90% sensitivity) [cir] 99% reproducibility between sequencers (if more than one sequencer is used) and between operators [cir] Lower limit of detection for SNV, indels, CNV must be stated. Laboratories must supply the following information in their application: [cir] Lower limit of % tumor accepted, and whether (and which) enrichment procedures are employed [cir] Whether the lab archives images of slides from the tumor [cir] Whether the lab also runs germline as well as tumor with the assay (a simultaneous germline sequencing is not required by NCI MATCH) [cir] A detailed description of assay procedures, including starting material, extraction of nucleic acids, quality assurance, quality metrics, data analysis and filters must be supplied. Laboratory NGS test panels must interrogate actionable mutations of interest (aMOIs) required for enrollment into the Rare Variant Arms (see table above). Applicant laboratories must state the MATCH arms in which they would like to participate. Academic laboratories must be located at a center that participates in NCI MATCH. As it is important that the dataset used for analysis in NCI MATCH be as robust as possible, the laboratory NGS test will require qualification, during which the performance of the laboratory will be compared with the NCI-MATCH central laboratory test to ensure good agreement with that assay. Concordance between the results from each lab and results of the NCI MATCH NGS assay run on an archived specimen will be tracked; if concordance falls below 90% for SNVs and indels, or 80% for CNVs, the laboratory must be willing to address these issues with the NCI MATCH team. If they cannot be addressed to the satisfaction of the NCI MATCH team, the laboratory may be eliminated from participation in NCI MATCH. Laboratories shall NOT advertise that they are screening laboratories for MATCH eligibility. Any press release or public disclosure requires clearance by NCI and NCI MATCH. Laboratories must agree to use the existing workflow established by the NCI MATCH trial to identify patients for the Rare Variant Arms. This includes use of the MATCH Rare Variant [[Page 35978]] template to identify aMOIs for submission to MATCHbox. [cir] Laboratory results of NGS assays done for clinical care will be the subject of this initiative. There is no funding for ``screening'' a patient for MATCH. [cir] Laboratories must notify NCI MATCH sites that the laboratory results would potentially allow the patient to be eligible for NCI MATCH. [cir] Laboratories must track how many assays per week detect rare variants that could make a patient eligible for NCI MATCH. [cir] If the clinician presents the MATCH study and the patient is eligible and desires to enter the study, the laboratory must agree to fill out a spreadsheet that can be used to put the results into the informatics system that assigns treatment in NCI MATCH (MATCHbox). [cir] Laboratories must have a way to answer questions from NCI MATCH sites about their assay and must have a contact person for optimal communication with the NCI MATCH team. Prior to participation, laboratories must enter into a collaboration agreement with NCI. A sample agreement is available upon request. As part of such a collaboration agreement, laboratories must agree to provide the licensing rights described in the CTEP IP Option to the Pharmaceutical Collaborators who provided agents for the NCI MATCH trial (https://ctep.cancer.gov/branches/rab/intellectual_property_optionto_collaborators.htm), as well as agree to the data sharing and publication rights consistent with those agreements. No reimbursement for these activities (testing or notification of sites of NCI MATCH eligibility) exists. Qualified laboratories serving underserved populations are encouraged to participate. How to apply: 1. Submit letter of interest (LOI) as described above under ``Letter of Interest and Collaboration Agreement'' to NCIMATCHLabApps@nih.gov. 2. LOIs will be accepted until January 31, 2018 at 5:00 p.m. Eastern Time. LOIs will be reviewed on a monthly basis, with those arriving by the 15th day of the month being reviewed and answered by the 15th day of the following month. 3. Notification of acceptance, non-acceptance or questions from Steering Committee will be sent to the designated contact person as soon as the LOI has been reviewed. This notification will include further instructions if a full application is invited. 4. Applications that have not been submitted within 3 months of notification of acceptance will be de-activated, and a new LOI must then be submitted if the laboratory wishes to participate in NCI MATCH. 5. DO NOT send a full application until you are invited to do so. Review criteria for LOI: Laboratory is a CLIA certified or accredited laboratory within the United States. Academic laboratories must have NCI MATCH open at their site. Laboratory has adequate sensitivity, specificity. Laboratory tests tumor tissue for rare variants as described in NCI MATCH. Laboratory agrees to provide needed information for evaluation of the analytical validity of the test. Laboratory is likely to refer at least 100 patients to NCI MATCH based on detection of rare variants in the past. Laboratory agrees to contact sites regarding NCI MATCH eligibility. Laboratory agrees to a collaboration with NCI as detailed above. Review criteria for full application: Laboratory NGS assay interrogates inclusionary and all exclusionary variants for arms in which the laboratory will participate. Laboratory supplies evidence that the assay meets analytical requirements as detailed above. Laboratories are capable of contacting clinical sites, tracking activity, and of referring at least 100 patients to the study based on detection of rare variants in the past. Laboratories agree to execute a collaboration agreement with NCI, as well as to data sharing and sharing publication rights. Laboratories agree to abide by the procedures in place for the MATCH study and to collaborate fully with the MATCH team. For more information, contact NCIMATCHLabApps@nih.gov. Dated: July 20, 2017. James V. Tricoli, Chief, Diagnostic Biomarkers and Technology Development Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute. [FR Doc. 2017-16203 Filed 8-1-17; 8:45 am] BILLING CODE 4140-01-P
![35976 Federal Register / Vol. 82, No. 147 / Wednesday, August 2, 2017 / Notices
applications, the disclosure of which Room 7323, MSC 5452, Bethesda, MD 20892, Molecular Analysis for Therapy Choice
would constitute a clearly unwarranted (301) 594–8843, stanfibr@niddk.nih.gov. (MATCH) trial leadership (NCT
invasion of personal privacy. Name of Committee: National Diabetes and 02465060) invites applications for
Digestive and Kidney Diseases Advisory Clinical Laboratory Improvements
Name of Committee: National Diabetes and Council; Digestive Diseases and Nutrition.
Digestive and Kidney Diseases Advisory Program (CLIA) certified/accredited
Date: September 6, 2017.
Council. laboratories that test tumor specimens
Open: 1:00 p.m. to 2:00 p.m.
Date: September 6, 2017. Agenda: To review the Division’s scientific from patients utilizing Next Generation
Open: 8:30 a.m. to 12:00 p.m. and planning activities. Sequencing (NGS) assays to participate
Agenda: To present the Director’s Report Place: National Institutes of Health, in the NCI MATCH trial. The NCI
and other scientific presentations. Natcher Building Forty-five, Natcher MATCH trial has implemented a new
Place: National Institutes of Health, Conference Center, Room F1, 45 Center process for identifying patients for arms
Natcher Building Forty-five, Conference Drive, Bethesda, MD 20892.
Rooms E1/E2, 45 Center Drive, Bethesda, MD
with rare variant eligibility criteria.
Closed: 2:15 p.m. to 3:30 p.m. Laboratories will contact any of the
20892. Agenda: To review and evaluate grant
Closed: 3:45 p.m. to 4:30 p.m. approximately 1100 sites that have
applications.
Agenda: To review and evaluate grant activated NCI MATCH if a specimen
Place: National Institutes of Health,
applications. Natcher Building Forty-five, Natcher sent from one of these sites has a rare
Place: National Institutes of Health, Conference Center, Room F1, 45 Center variant that would potentially make the
Natcher Building Forty-five, Conference Drive, Bethesda, MD 20892. patient eligible for one of the treatment
Rooms E1/E2, 45 Center Drive, Bethesda, MD Contact Person: Brent B. Stanfield, Ph.D., arms open in this initiative.
20892. Director, Division of Extramural Activities,
Contact Person: Brent B. Stanfield, Ph.D., DATES: LOIs should be submitted to the
National Institutes of Diabetes and Digestive National Cancer Institute (NCI),
Director, Division of Extramural Activities, and Kidney Diseases, 6707 Democracy Blvd.
National Institutes of Diabetes and Digestive National Institutes of Health (NIH) on or
Room 7323, MSC 5452, Bethesda, MD 20892,
and Kidney Diseases, 6707 Democracy Blvd. (301) 594–8843, stanfibr@niddk.nih.gov.
before 5:00 p.m. EST on January 31,
Room 7323, MSC 5452, Bethesda, MD 20892, 2018.
(301) 594–8843, stanfibr@niddk.nih.gov. Any interested person may file written
comments with the committee by forwarding ADDRESSES: Submit LOIs by email to
Name of Committee: National Diabetes and the statement to the Contact Person listed on NCIMATCHLabApps@nih.gov. 9609
Digestive and Kidney Diseases Advisory this notice. The statement should include the
Council; Diabetes, Endocrinology and
Medical Center Drive, 3 West, Room
name, address, telephone number and when 526, MSC 9728, Rockville, MD 20892.
Metabolic Diseases. applicable, the business or professional
Date: September 6, 2017. FOR FURTHER INFORMATION CONTACT:
affiliation of the interested person.
Closed: 1:00 p.m. to 2:00 p.m. In the interest of security, NIH has Questions about this request for LOIs
Agenda: To review and evaluate grant instituted stringent procedures for entrance should be directed to
applications. onto the NIH campus. All visitor vehicles, NCIMATCHLabApps@nih.gov. James V.
Place: National Institutes of Health, including taxicabs, hotel, and airport shuttles Tricoli tricolij@mail.nih.gov can also
Natcher Building Forty-five, Natcher will be inspected before being allowed on
Conference Center, Room E1, 45 Center
provide further information.
campus. Visitors will be asked to show one SUPPLEMENTARY INFORMATION: NCI–
Drive, Bethesda, MD 20892. form of identification (for example, a
Open: 2:00 p.m. to 3:30 p.m. MATCH aims to establish whether
government-issued photo ID, driver’s license,
Agenda: To review the Division’s scientific
or passport) and to state the purpose of their patients with tumor mutations,
and planning activities. amplifications or translocations in one
visit.
Place: National Institutes of Health, of the genetic pathways of interest are
Information is also available on the
Natcher Building Forty-five, Natcher likely to derive clinical benefit (primary
Institute’s/Center’s home page:
Conference Center, Room E1, 45 Center
Drive, Bethesda, MD 20892.
www.niddk.nih.gov/fund/divisions/DEA/ objective: Objective response; secondary
Council/coundesc.htm., where an agenda and objective: Progression-free survival of at
Contact Person: Brent B. Stanfield, Ph.D.,
any additional information for the meeting least 6 months) if treated with agents
Director, Division of Extramural Activities,
will be posted when available. targeting that specific pathway in a
National Institutes of Diabetes and Digestive
and Kidney Diseases, 6707 Democracy Blvd. (Catalogue of Federal Domestic Assistance single-arm design (see current arms
Room 7323, MSC 5452, Bethesda, MD 20892, Program Nos. 93.847, Diabetes, below).
(301) 594–8843, stanfibr@niddk.nih.gov. Endocrinology and Metabolic Research; Patients with histologically
93.848, Digestive Diseases and Nutrition
Name of Committee: National Diabetes and documented solid tumors, lymphomas
Research; 93.849, Kidney Diseases, Urology
Digestive and Kidney Diseases Advisory and multiple myeloma whose disease
and Hematology Research, National Institutes
Council; Kidney, Urologic and Hematologic has progressed following at least one
of Health, HHS)
Diseases. line of standard systemic therapy or for
Date: September 6, 2017. Dated: July 27, 2017.
whom no standard therapy exists are
Open: 1:00 p.m. to 3:00 p.m. David Clary,
Agenda: To review the Division’s scientific
eligible if they meet the eligibility
Program Analyst, Office of Federal Advisory criteria for the trial. Further information
and planning activities. Committee Policy.
Place: National Institutes of Health, about the NCI–MATCH trial may be
Natcher Building Forty-five, Natcher [FR Doc. 2017–16192 Filed 8–1–17; 8:45 am] found at http://ecog-acrin.org/trials/nci-
Conference Center, Room F2, 45 Center BILLING CODE 4140–01–P match-eay131.
Drive, Bethesda, MD 20892. The selected collaborating
Closed: 3:00 p.m. to 3:30 p.m. laboratories may only act (i.e., refer
Agenda: To review and evaluate grant DEPARTMENT OF HEALTH AND patients) on any of the rare variant arms
applications. HUMAN SERVICES
sradovich on DSKBCFCHB2PROD with NOTICES
for which their assay reports actionable
Place: National Institutes of Health, mutations of interest (aMOIs). The assay
Natcher Building Forty-five, Natcher National Institutes of Health
Conference Center, Room F2, 45 Center
must also report all exclusionary
Drive, Bethesda, MD 20892. Request for Letters of Interest for NCI– variants for the arm unless these occur
Contact Person: Brent B. Stanfield, Ph.D., MATCH Laboratories at a frequency of >1% in cancer
Director, Division of Extramural Activities, patients.
National Institutes of Diabetes and Digestive SUMMARY: The National Cancer Institute CLIA accredited/certified laboratories
and Kidney Diseases, 6707 Democracy Blvd. (NCI) in collaboration with the NCI located in the United States may be
VerDate Sep<11>2014 19:43 Aug 01, 2017 Jkt 241001 PO 00000 Frm 00051 Fmt 4703 Sfmt 4703 E:\FR\FM\02AUN1.SGM 02AUN1](https://thefederalregister.org/doc/82_FR_36123/page/1.svg)
![35978 Federal Register / Vol. 82, No. 147 / Wednesday, August 2, 2017 / Notices
template to identify aMOIs for 4. Applications that have not been DEPARTMENT OF HEALTH AND
submission to MATCHbox. submitted within 3 months of HUMAN SERVICES
Æ Laboratory results of NGS assays done notification of acceptance will be de-
for clinical care will be the subject of activated, and a new LOI must then be National Institutes of Health
this initiative. There is no funding for submitted if the laboratory wishes to
‘‘screening’’ a patient for MATCH. National Cancer Institute; Notice of
participate in NCI MATCH.
Æ Laboratories must notify NCI MATCH Closed Meeting
5. DO NOT send a full application
sites that the laboratory results would
until you are invited to do so. Pursuant to section 10(d) of the
potentially allow the patient to be
Review criteria for LOI: Federal Advisory Committee Act, as
eligible for NCI MATCH.
Æ Laboratories must track how many amended (5 U.S.C. Appendix 2); notice
• Laboratory is a CLIA certified or is hereby given of the following
assays per week detect rare variants accredited laboratory within the United
that could make a patient eligible for meeting.
States. The meeting will be closed to the
NCI MATCH.
Æ If the clinician presents the • Academic laboratories must have public in accordance with the
MATCH study and the patient is NCI MATCH open at their site. provisions set forth in sections 552b(c)
eligible and desires to enter the • Laboratory has adequate sensitivity, (4) and 552b(c) (6), Title 5 U.S.C., as
study, the laboratory must agree to specificity. amended. The purpose of this meeting
fill out a spreadsheet that can be is to evaluate requests for preclinical
• Laboratory tests tumor tissue for development resources for potential
used to put the results into the
rare variants as described in NCI new therapeutics for the treatment of
informatics system that assigns
treatment in NCI MATCH MATCH. cancer. The outcome of the evaluation
(MATCHbox). • Laboratory agrees to provide needed will provide information to internal NCI
Æ Laboratories must have a way to information for evaluation of the committees that will decide whether
answer questions from NCI MATCH analytical validity of the test. NCI should support requests and make
sites about their assay and must • Laboratory is likely to refer at least available contract resources for
have a contact person for optimal development of the potential
100 patients to NCI MATCH based on
communication with the NCI therapeutic to improve the treatment of
detection of rare variants in the past.
MATCH team. various forms of cancer. The research
• Prior to participation, laboratories • Laboratory agrees to contact sites proposals and the discussions could
must enter into a collaboration regarding NCI MATCH eligibility. disclose confidential trade secrets or
agreement with NCI. A sample • Laboratory agrees to a collaboration commercial property such as patentable
agreement is available upon request. As with NCI as detailed above. material, and personal information
part of such a collaboration agreement, concerning individuals associated with
laboratories must agree to provide the Review criteria for full application:
the proposed research projects, the
licensing rights described in the CTEP • Laboratory NGS assay interrogates disclosure of which would constitute a
IP Option to the Pharmaceutical inclusionary and all exclusionary clearly unwarranted invasion of
Collaborators who provided agents for variants for arms in which the personal privacy.
the NCI MATCH trial (https:// laboratory will participate. Name of Committee: National Cancer
ctep.cancer.gov/branches/rab/ • Laboratory supplies evidence that Institute Special Emphasis Panel; Jun2017
intellectual_property_optionto_ the assay meets analytical requirements Cycle 26 NExT SEP Committee Meeting.
collaborators.htm), as well as agree to as detailed above. Date: August 31, 2017.
the data sharing and publication rights Time: 8:30 a.m. to 4:30 p.m.
consistent with those agreements. • Laboratories are capable of Agenda: To evaluate the NCI Experimental
• No reimbursement for these contacting clinical sites, tracking Therapeutics Program Portfolio.
activities (testing or notification of sites activity, and of referring at least 100 Place: National Institutes of Health, 9000
of NCI MATCH eligibility) exists. patients to the study based on detection Rockville Pike, Building 31, Wing C, 6th
Floor, Conference Room 10, Bethesda, MD
Qualified laboratories serving of rare variants in the past. 20892.
underserved populations are • Laboratories agree to execute a Contact Persons: Barbara Mroczkowski,
encouraged to participate. collaboration agreement with NCI, as Ph.D., Executive Secretary, Discovery
How to apply: Experimental Therapeutics Program,
1. Submit letter of interest (LOI) as well as to data sharing and sharing
National Cancer Institute, NIH, 31 Center
described above under ‘‘Letter of publication rights.
Drive, Room 3A44, Bethesda, MD 20817
Interest and Collaboration Agreement’’ • Laboratories agree to abide by the (301) 496–4291, mroczkoskib@mail.nih.gov.
to NCIMATCHLabApps@nih.gov. procedures in place for the MATCH Toby Hecht, Ph.D., Executive Secretary,
2. LOIs will be accepted until January study and to collaborate fully with the Development Experimental Therapeutics
31, 2018 at 5:00 p.m. Eastern Time. LOIs MATCH team. Program, National Cancer Institute, NIH,
will be reviewed on a monthly basis, 9609 Medical Center Drive, Room 3W110,
For more information, contact Rockville, MD 20850, (240) 276–5683,
with those arriving by the 15th day of
NCIMATCHLabApps@nih.gov. toby.hecht2@nih.gov.
the month being reviewed and answered
by the 15th day of the following month. Dated: July 20, 2017. (Catalogue of Federal Domestic Assistance
3. Notification of acceptance, non- Program Nos. 93.392, Cancer Construction;
sradovich on DSKBCFCHB2PROD with NOTICES
James V. Tricoli,
acceptance or questions from Steering 93.393, Cancer Cause and Prevention
Chief, Diagnostic Biomarkers and Technology Research; 93.394, Cancer Detection and
Committee will be sent to the Development Branch, Cancer Diagnosis Diagnosis Research; 93.395, Cancer
designated contact person as soon as the Program, Division of Cancer Treatment and Treatment Research; 93.396, Cancer Biology
LOI has been reviewed. This Diagnosis, National Cancer Institute. Research; 93.397, Cancer Centers Support;
notification will include further [FR Doc. 2017–16203 Filed 8–1–17; 8:45 am] 93.398, Cancer Research Manpower; 93.399,
instructions if a full application is BILLING CODE 4140–01–P
Cancer Control, National Institutes of Health,
invited. HHS)
VerDate Sep<11>2014 19:43 Aug 01, 2017 Jkt 241001 PO 00000 Frm 00053 Fmt 4703 Sfmt 4703 E:\FR\FM\02AUN1.SGM 02AUN1](https://thefederalregister.org/doc/82_FR_36123/page/3.svg)
Document Created: 2017-08-02 07:09:31
Document Modified: 2017-08-02 07:09:31
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Dates | LOIs should be submitted to the National Cancer Institute (NCI), National Institutes of Health (NIH) on or before 5:00 p.m. EST on January 31, 2018. | |
| Contact | Questions about this request for LOIs should be directed to [email protected] James V. Tricoli [email protected] can also provide further information. | |
| FR Citation | 82 FR 35976 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR